Home›Stock Screener›Wockhardt›Intrinsic Value

Wockhardt Intrinsic Value

Wockhardt intrinsic value. Wockhardt (WOCKPHARMA) median intrinsic value is ₹874.80 from 9 valuation models (range ₹656–₹1304), vs current price ₹2187.00 — -60.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Analyse WOCKPHARMA shareholding pattern to track promoter, FII and institutional holdings.

Market Price (CMP)
₹2187.00
Primary Intrinsic Value
₹656.10
Market Cap
₹177.1K Cr
-60.0% Downside
Median Value
₹874.80
Value Range
₹656 - ₹1304
Assessment
Trading Above Calculated Value
Safety Margin
-100.0%

WOCKPHARMA Valuation Methods Summary — DCF, Graham Number & P/E

Wockhardt intrinsic value across 9 models vs current price ₹2187.00 — upside/downside and value range per method. For current market price and key ratios, visit Wockhardt screener.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹656.10 ₹524.88 - ₹787.32 -70.0% EPS: ₹19.40, Sector P/E: 22x
Book Value Method asset ₹1303.95 ₹1173.56 - ₹1434.35 -40.4% Book Value/Share: ₹651.98, P/B: 2.0x
Revenue Multiple Method revenue ₹967.90 ₹871.11 - ₹1064.69 -55.7% Revenue/Share: ₹483.95, P/S: 2.0x
EBITDA Multiple Method earnings ₹908.64 ₹817.78 - ₹999.50 -58.5% EBITDA: ₹736.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹874.80 ₹699.84 - ₹1049.76 -60.0% CF Growth: 5.0%, Discount: 15%
PEG Ratio Method growth ₹656.10 ₹590.49 - ₹721.71 -70.0% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹656.10 ₹590.49 - ₹721.71 -70.0% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹1093.50 ₹984.15 - ₹1202.85 -50.0% ROE: 5.5%, P/E Multiple: 10x
Graham Defensive Method conservative ₹656.10 ₹590.49 - ₹721.71 -70.0% EPS: ₹19.40, BVPS: ₹651.98
Method Types: Earnings Asset DCF Growth Dividend Conservative

WOCKPHARMA Intrinsic Value vs Market Price — All Valuation Models

Wockhardt fair value range ₹656–₹1304 vs current market price ₹2187.00 across 9 valuation models. Browse WOCKPHARMA financial statements for revenue, profit, balance sheet and cash flow data.

WOCKPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?

Wockhardt median intrinsic value ₹874.80, current price ₹2187.00 — Trading Above Calculated Value by 60.0%, margin of safety -100.0%.

What is the intrinsic value of WOCKPHARMA?

Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Wockhardt (WOCKPHARMA) is ₹874.80 (median value). With the current market price of ₹2187.00, this represents a -60.0% variance from our estimated fair value.

The valuation range spans from ₹656.10 to ₹1303.95, indicating ₹656.10 - ₹1303.95.

Is WOCKPHARMA undervalued or overvalued?

Based on our multi-method analysis, Wockhardt (WOCKPHARMA) appears to be trading above calculated value by approximately 60.0%.

WOCKPHARMA Financial Health — Key Ratios vs Industry Benchmarks

Wockhardt financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 5.5% Industry Standard: 15%+ Below 10% Measures shareholder return efficiency
Operating Margin 18.0% Industry Standard: 20%+ Above 10% Indicates operational efficiency level
Asset Turnover Ratio 0.46x Industry Standard: 1.0x+ Below 0.5x Measures asset utilization efficiency

WOCKPHARMA Cash Flow Quality — Operating & Free Cash Flow

Wockhardt operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹390 Cr ₹275 Cr Positive Free Cash Flow 8/10
March 2025 ₹-22 Cr ₹-412 Cr Negative Cash Flow 3/10
March 2024 ₹219 Cr ₹150 Cr Positive Free Cash Flow 8/10
March 2023 ₹153 Cr ₹94 Cr Positive Free Cash Flow 8/10
March 2022 ₹413 Cr ₹311 Cr Positive Free Cash Flow 8/10